NGEN Stock Overview
Engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
NervGen Pharma Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.24 |
| 52 Week High | CA$3.98 |
| 52 Week Low | CA$1.58 |
| Beta | 1.35 |
| 11 Month Change | -3.45% |
| 3 Month Change | -20.57% |
| 1 Year Change | 14.87% |
| 33 Year Change | -16.73% |
| 5 Year Change | 58.87% |
| Change since IPO | 28.74% |
Recent News & Updates
We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate
Oct 23
We're Interested To See How NervGen Pharma (CVE:NGEN) Uses Its Cash Hoard To Grow
Jun 11Recent updates
We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate
Oct 23We're Interested To See How NervGen Pharma (CVE:NGEN) Uses Its Cash Hoard To Grow
Jun 11Is NervGen Pharma (CVE:NGEN) In A Good Position To Invest In Growth?
Dec 22Here's Why We're Watching NervGen Pharma's (CVE:NGEN) Cash Burn Situation
Aug 30Will NervGen Pharma (CVE:NGEN) Spend Its Cash Wisely?
Apr 04NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 31% Below Their Intrinsic Value Estimate
Feb 02We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate
Nov 23We Think NervGen Pharma (CVE:NGEN) Needs To Drive Business Growth Carefully
Jun 29We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate
Mar 16We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate
Mar 08Shareholder Returns
| NGEN | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -16.4% | -6.1% | 0.7% |
| 1Y | 14.9% | -22.3% | 21.7% |
Return vs Industry: NGEN exceeded the Canadian Pharmaceuticals industry which returned -22.8% over the past year.
Return vs Market: NGEN underperformed the Canadian Market which returned 21.4% over the past year.
Price Volatility
| NGEN volatility | |
|---|---|
| NGEN Average Weekly Movement | 9.8% |
| Pharmaceuticals Industry Average Movement | 11.5% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: NGEN has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: NGEN's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Mike Kelly | www.nervgen.com |
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer’s disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage.
NervGen Pharma Corp. Fundamentals Summary
| NGEN fundamental statistics | |
|---|---|
| Market cap | CA$160.19m |
| Earnings (TTM) | -CA$24.01m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.6x
P/E RatioIs NGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NGEN income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$24.01m |
| Earnings | -CA$24.01m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NGEN perform over the long term?
See historical performance and comparison